drugset / Trial / NCT03509922

A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity

NCT03509922

Phase 4 Completed 60 enrolled Yuhan Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to evaluate the effect of sarpogrelate on blood viscosity after 24 weeks in patients with high blood viscosity.

Timeline

Start
2018-10-11
Primary completion
2019-12-26
Completion
2020-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarpogrelate Small molecule 100 mg